Daiwa Securities Group Inc. Has $599,000 Stock Holdings in UiPath Inc. (NYSE:PATH)

Daiwa Securities Group Inc. increased its position in UiPath Inc. (NYSE:PATH) by 9.5% in the fourth quarter, Holdings Channel.com reports. The firm owned 24,100 shares of the healthcare company’s stock after acquiring an additional 2,100 shares during the period. Daiwa Securities Group Inc.’s holdings in UiPath were worth $599,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the business. CWM LLC raised its position in shares of UiPath by 19.6% during the 3rd quarter. CWM LLC now owns 8,799 shares of the healthcare company’s stock valued at $151,000 after acquiring an additional 1,439 shares during the last quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund boosted its holdings in UiPath by 104.4% during the third quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 102,000 shares of the healthcare company’s stock worth $1,745,000 after buying an additional 52,100 shares during the last quarter. Robeco Institutional Asset Management B.V. raised its position in shares of UiPath by 196.8% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 332,715 shares of the healthcare company’s stock valued at $5,693,000 after acquiring an additional 220,618 shares during the period. Xponance Inc. boosted its stake in UiPath by 3.9% during the 3rd quarter. Xponance Inc. now owns 44,846 shares of the healthcare company’s stock worth $767,000 after acquiring an additional 1,694 shares during the last quarter. Finally, Raymond James & Associates grew its holdings in UiPath by 51.0% during the third quarter. Raymond James & Associates now owns 89,534 shares of the healthcare company’s stock valued at $1,532,000 after purchasing an additional 30,244 shares during the period. 62.50% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on PATH. TD Cowen boosted their price target on shares of UiPath from $25.00 to $28.00 and gave the company an “outperform” rating in a report on Thursday, March 14th. Royal Bank of Canada restated a “sector perform” rating and issued a $29.00 price target on shares of UiPath in a report on Monday, April 1st. JPMorgan Chase & Co. upgraded shares of UiPath from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $22.00 to $28.00 in a report on Thursday, March 14th. Bank of America upped their price target on shares of UiPath from $26.00 to $30.00 and gave the company a “buy” rating in a report on Thursday, March 14th. Finally, DA Davidson raised their price objective on shares of UiPath from $20.00 to $24.00 and gave the stock a “neutral” rating in a report on Thursday, March 14th. Nine equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $27.41.

Insider Buying and Selling at UiPath

In other news, CFO Ashim Gupta sold 16,000 shares of the firm’s stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $22.84, for a total transaction of $365,440.00. Following the completion of the sale, the chief financial officer now owns 87,505 shares in the company, valued at approximately $1,998,614.20. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders have sold a total of 72,000 shares of company stock worth $1,591,360 over the last ninety days. Insiders own 31.03% of the company’s stock.

UiPath Trading Down 1.4 %

UiPath stock opened at $19.42 on Friday. The stock has a 50-day simple moving average of $22.30 and a 200 day simple moving average of $21.53. UiPath Inc. has a 52 week low of $12.38 and a 52 week high of $27.87.

UiPath (NYSE:PATH) last posted its earnings results on Wednesday, March 13th. The healthcare company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.10. UiPath had a negative return on equity of 3.29% and a negative net margin of 6.87%. The business had revenue of $405.25 million for the quarter, compared to analyst estimates of $383.32 million. On average, sell-side analysts anticipate that UiPath Inc. will post -0.04 earnings per share for the current year.

About UiPath

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.